Researchers engineered a tetrahedral DNA nanocage (TAF) that delivers the senolytic compound fisetin and miR-29-targeting antisense oligonucleotides through photo-triggered release mechanisms. The platform addresses age-related wound healing impairment by sequentially targeting three distinct repair phases: DNA components scavenge excess reactive oxygen species during inflammation, light-activated antisense oligonucleotide release promotes collagen synthesis during proliferation, and sustained fisetin delivery eliminates senescent cells throughout healing. This represents a significant advancement in precision medicine for aging biology. Traditional wound treatments fail in older adults because they don't account for the dysregulated temporal dynamics and accumulated cellular senescence that characterize aged tissue repair. The TAF platform's programmable, stage-specific intervention directly addresses these core mechanisms of impaired healing. While the mouse model demonstrates proof-of-concept, translating this sophisticated nanotechnology to human applications faces substantial hurdles including manufacturing complexity, regulatory approval for novel DNA therapeutics, and determining optimal dosing protocols. The work nonetheless establishes a compelling framework for temporal programming of anti-aging interventions, potentially applicable beyond wound healing to other age-related tissue dysfunction.